Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Umetani, N.
Right arrow Articles by Nagawa, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Umetani, N.
Right arrow Articles by Nagawa, H.
Related Collections
Right arrow Other Colorectal

Annals of Surgical Oncology, Vol 7, Issue 4 276-280, Copyright © 2000 by Society of Surgical Oncology

ARTICLES

Diagnostic primer sets for microsatellite instability optimized for a minimal amount of damaged DNA from colorectal tissue samples

N. Umetani, S. Sasaki, T. Watanabe, H. Ishigami, E. Ueda and H. Nagawa
Department of Surgical Oncology, School of Medicine, University of Tokyo, Japan. umetani-1su@h.u-tokyo.ac.jp

BACKGROUND: The diagnosis of microsatellite instability from a minimal amount of highly damaged DNA, extracted from formalin-fixed, paraffin-embedded tissue by the microdissection method, is difficult. Therefore, optimized primer sets were newly designed for substitution of documented ones. METHODS: DNA was extracted from 15 archival colorectal carcinomas and used as templates for polymerase chain reaction. Nine standard microsatellite markers (BAT-25, BAT-26, BAT-40, D18S69, D2S123, D5S346, D10S197, D17S250, and D18S58) were selected for diagnosis of microsatellite instability in colorectal carcinomas. All polymerase chain reaction conditions for primer sets were unified to save experimental time. RESULTS: The primer sets for the latter five markers documented in the literature were redesigned because of poor efficiency for damaged DNA. As a result, the number of DNA samples, sufficiently amplified at all markers, improved from 0% to 93%. CONCLUSIONS: Diagnostic primer sets for microsatellite instability, optimized for a minimal amount of damaged DNA from colorectal tissue samples, were established.


This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
Y. Kazama, T. Watanabe, T. Kanazawa, J. Tanaka, T. Tanaka, and H. Nagawa
Microsatellite instability in poorly differentiated adenocarcinomas of the colon and rectum: relationship to clinicopathological features
J. Clin. Pathol., June 1, 2007; 60(6): 701 - 704.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Ishikawa, T. Fujita, Y. Suzuki, S. Okabe, Y. Yuasa, T. Iwai, and Y. Kawakami
Tumor-specific Immunological Recognition of Frameshift-mutated Peptides in Colon Cancer with Microsatellite Instability
Cancer Res., September 1, 2003; 63(17): 5564 - 5572.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G.M. Nash, M. Gimbel, J. Shia, A.T. Culliford, D.R. Nathanson, M. Ndubuisi, Y. Yamaguchi, Z.S. Zeng, F. Barany, and P.B. Paty
Automated, Multiplex Assay for High-Frequency Microsatellite Instability in Colorectal Cancer
J. Clin. Oncol., August 15, 2003; 21(16): 3105 - 3112.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
C. P. Theuer, B. S. Campbell, D. J. Peel, F. Lin, P. Carpenter, A. Ziogas, and J. A. Butler
Microsatellite Instability in Japanese vs European American Patients With Gastric Cancer
Arch Surg, August 1, 2002; 137(8): 960 - 966.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-W. Choi, K. J. Lee, Y.-A. Bae, K.-O. Min, M.-S. Kwon, K.-M. Kim, and M.-G. Rhyu
Genetic Classification of Colorectal Cancer Based on Chromosomal Loss and Microsatellite Instability Predicts Survival
Clin. Cancer Res., July 1, 2002; 8(7): 2311 - 2322.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the Society of Surgical Oncology.